Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012544 | 0.85 | CYP19A1 (0.34) | MAPTGAAKDM4ERAPGEF4CRHR1 | |
| SCHEMBL7006275 | 0.81 | LMNA (0.35) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL7007793 | 0.79 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7007327 | 0.77 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6094470 | 0.72 | CRHR1 (0.33) | GAAKDM4EALDH1A1CRHR1 | |
| SCHEMBL7004385 | 0.66 | MAPT (0.37) | MAPTGAAKDM4EALDH1A1HTT | |
| SCHEMBL7010054 | 0.66 | CDK5 (0.33) | MAPTHTTRAPGEF4CRHR1 | |
| SCHEMBL6095943 | 0.65 | LMNA (0.36) | MAPTGAAKDM4EALDH1A1CRHR1 | |
| SCHEMBL7006813 | 0.61 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL5208719 | 0.60 | CRHR1 (0.35) | GAAKDM4EHTTCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086103-B1 | PYRIDO 2,3-B]INDOLIZINE DERIVATIVES AND AZA ANALOGUES THEREOF; CRF 1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6495686-B2 | THERAPY FOR PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020019525-A1 | Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands | NEUROGEN | 2002-02-14 | — | — | US | disclosed |
| US-6194574-B1 | SELECTIVELY BIND TO CORTICOTROPIN-RELEASING FACTOR (CRF1) RECEPTORS; FOR TREATING STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019525-A1 | Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands | CRHR1, HTR1D, HTR5A | MAPT 4631/4885GAA 4647/4885KDM4E 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.